Climb Bio licenses CLYM116, an anti-APRIL antibody, expanding its immune-mediated disease pipeline, with preclinical data expected in 2025. Climb Bio, Inc. has announced an exclusive licensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback